lebrikizumab (Ebglyss)
Jump to navigation
Jump to search
Indications
- treatment of atopic dermatitis (FDA-approved Sept 2024)
* FDA denied approval of lebrikizumab for treatment of atopic dermatitis in Oct 2023
Dosage
- 500 mg (2 250 mg injections) at baseline & week 2
- follow by 250 mg every 2 weeks until week 16 or later when adequate clinical response is achieved
- maintenance: 250 mg every 4 weeks
Adverse effects
- eye & eyelid inflammation
- injection site reactions
- herpes zoster (shingles)
More general terms
References
- ↑ Reuters. Oct 2, 2023 U.S. FDA declines to approve Eli Lilly's drug to treat eczema https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-eli-lillys-skin-disease-drug-2023-10-02/
- ↑ Brunk D FDA Approves Lebrikizumab for Atopic Dermatitis Medscape. September 14, 2024 https://www.medscape.com/viewarticle/fda-approves-lebrikizumab-atopic-dermatitis-2024a1000gpu